Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $196.2 million.

  • Pharming's Non-Current Assets rose 3688.41% to $196.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year increase of 3688.41%. This contributed to the annual value of $121.5 million for FY2024, which is 1704.09% down from last year.
  • According to the latest figures from Q3 2025, Pharming's Non-Current Assets is $196.2 million, which was up 3688.41% from $200.5 million recorded in Q2 2025.
  • Pharming's 5-year Non-Current Assets high stood at $200.5 million for Q2 2025, and its period low was $130275.0 during Q3 2022.
  • For the 5-year period, Pharming's Non-Current Assets averaged around $130.9 million, with its median value being $145.3 million (2024).
  • Per our database at Business Quant, Pharming's Non-Current Assets tumbled by 9991.79% in 2022 and then soared by 11099575.9% in 2023.
  • Quarter analysis of 5 years shows Pharming's Non-Current Assets stood at $149250.5 in 2021, then surged by 99261.15% to $148.3 million in 2022, then decreased by 1.2% to $146.5 million in 2023, then dropped by 17.04% to $121.5 million in 2024, then soared by 61.41% to $196.2 million in 2025.
  • Its Non-Current Assets was $196.2 million in Q3 2025, compared to $200.5 million in Q2 2025 and $189.1 million in Q1 2025.